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A B S T R A C T
We present the rare case of a fatal anaphylactic reaction to gadobutrol, a magnetic reso-
nance imaging contrast agent, in a 42-year-old man.The patient underwent elective magnetic
resonance imaging for diagnostic clarification of a suspicious finding in the abdomen. The
patient had undergone contrast-enhanced computed tomography previously without the
occurrence of any adverse effects. Adverse drug reactions in gadobutrol have a very low prev-
alence of 0.32%-3.5%, with serious adverse drug reactions in <0.1%. There are only a few
cases of fatal anaphylactoid reactions to gadolinium-based contrast agents in general. However,
if an anaphylactoid reaction occurs, it can present itself with a fulminant course within
minutes.
© 2017 the Authors. Published by Elsevier Inc. under copyright license from the University
ofWashington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Case history
A 42-year-old man underwent elective magnetic resonance
imaging (MRI) for diagnostic clarification of a suspicious finding
in the abdomen.The patient had undergone contrast-enhanced
computed tomography previously without the occurrence of
any adverse effects.
A fewminutes after the application of the MRI contrast agent
Gadovist (active substance: gadobutrol), the patient pressed the
alarm button complaining first about nausea, then also dyspnea.
With the suspected diagnosis of an allergic reaction, the patient
was administered an ampoule of the antihistamineTavegyl (2mg/
2 mL, active substance: clemastine), the H2-receptor-antagonist
Zantic (50 mg/5 mL, active substance: ranitidine), and the
glucocorticoid Fortecortin (40 mg/5 mL, active substance: dexa-
methasone) intravenously.The patient developed cold sweat, his
pulse was hardly any more palpable, and he lost conscious-
ness. Defibrillation pads were placed, the heart frequency was
analyzed, and cardiac massage had to be started.With progres-
sive swelling of the airways, the patient also had to be intubated.
Resuscitation was performed for approximately 1 hour during
which time the patient was transferred to the university hos-
pital.The patient was then hemodynamically stable but sedated
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and ventilated. In the blood samples obtained upon admission
to the hospital, the enzyme tryptase was considerably elevated
(>200 µg/L, normal <11.4 µg/L).
Therapy with antihistamines and steroids was continued.
The patient’s body was kept at a maximum of 36°C (96.8°F) to
prevent further brain damage. Yet, cranial computed tomog-
raphy 1 day later showed a reduced differentiation of the brain
cortex and the medulla, missing contrast of the basal ganglia
and general brain edema as a result of severe lack of oxygen
(Fig. 1).With an overall poor prognosis and in consultation with
the relatives, it was decided to stop all intensive care treat-
ments. The patient died 2 days later.
Autopsy
Autopsy showed massive brain edema (1450 g, Fig. 2), venous
congestion, and mild thorax trauma due to the resuscitation
measurements (rib fractures and subcutaneous hemorrhage
near the sternum). Besides massive brain edema, no other find-
ings causative of death could be found.The cause of death was
therefore determined to be paralysis of the respiratory system
due to brain edema following lack of oxygen during long-
lasting resuscitation measurements in consequence to the
anaphylactic reaction to the MRI contrast agent Gadovist.
Discussion
There are several gadolinium-based contrast agents for contrast-
enhanced MRI that are approved for clinical use. Consisting
of a paramagnetic metal, they increase signal intensity and
thereby tissue contrast in MRI. The contrast agent adminis-
tered in the present case was gadobutrol (Gadovist; Bayer
Schering Pharma AG, Berlin, Germany), a highly stable, non-
ionic, macrocyclic gadoliniumMRI contrast agent that was first
introduced in Switzerland in 1998 [1]. Gadobutrol distributes
rapidly into the extracellular space and is eliminated by glo-
merular filtration [2]. Gadobutrol has been placed in the lowest-
risk category for the development of nephrogenic systemic
fibrosis in patients with renal impairment [1,3]. Adverse drug
reactions (ADRs) for gadobutrol were reported in 0.32%-3.8%
[1,2,4,5], mostly in terms of nausea, vomiting, urticaria, and diz-
ziness, with serious ADRs in <0.1% [1,2,4,5]. The onset of ADRs
occurred within 5 minutes in 62% [2] to 82.4% [4] of the pa-
tients. Most of the rest of the ADRs occurred within 15 [4] to
24 hours [2]. In the electronic database FDA Adverse Event Re-
porting System of the United States, there are 614 cases reported
of ADRs to gadolinium-based contrast agents in general (1998-
2012), of which 7.2% had a fatal outcome [6].
Conclusion
Anaphylactic reaction to an MRI contrast agent is a very rare
complication [6,7] but can have a relentless course within
minutes when it occurs. Even in a medical setting with highly
trained professionals, the outcome can be fatal. Therefore, on
the one hand, it is important for clinicians to know that even
Fig. 1 – Computed tomography (axial view) of the
edematous brain, 1 day after the incident.
Fig. 2 – Photography of the edematous brain (1450 g) at autopsy. (A) Caudal view. (B) Cranial view.
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at MRI examinations, fatal accidents can occur quite sud-
denly and tomake sure resuscitation equipment as well as well-
trained staff is available all the time [8]. Forensic pathologists,
on the other hand, have to be aware of those rare causes of
fatal anaphylactic reactions while investigating sudden death
after medical treatments or examinations.
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